Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional)

From US Department of Health & Human Services: National Institutes of Health (NIH)

The National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services, is the nation’s medical research agency — making important discoveries that improve health and save lives.

Type of Support

Overview

This Notice of Funding Opportunity (NOFO) focuses on encouraging Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) aimed at the development of novel, evidence-based, FDA-regulated medical products designed to meet the needs of patients suffering from opioid use disorders (OUD) and/or stimulant use disorders (StUD). These applications are sought in two specific scientific areas: pharmacotherapeutics, including small molecules and biologics, and medical therapeutic and diagnostic devices, which also encompass software as a medical device. The overarching goal of this NOFO is to augment the fight against the national crisis posed by opioids and psychostimulants by facilitating the introduction of new medical products to aid individuals, families, and communities impacted by these substance use disorders. It particularly welcomes applications from small businesses currently marketing technologies or developing new technologies for different medical indications but are now looking to demonstrate potential applications of their FDA-regulated products for OUD/StUD.

Eligibility

Organization's Location
labore eu
Program Location
in
Organization Type
up to 2.5M

Submission

Schedule
Step 1: et quis cupidatat
Application deadline
Dec 22, 2024
Step 2: commodo dolor (magna voluptate)

Similar grants